ClinicalTrials.gg
RecruitingNCT03177122Updated Jul 20, 2023

Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology

A Phase 4 interventional study of Myo-inositol in Sterility and Infertility, sponsored by American University of Beirut Medical Center. Recruiting at 1 site in Lebanon. Open to female participants aged 18 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by American University of Beirut Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2017; still recruiting 9 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 18 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing inositol in Infertility — 1 open to participants now, 1 under way, none of them phase 3. Inositol · Infertility.

Planned enrollment
6th of 10
100 · median 118
Started
2017
the only one that year
Phase 4
2 of 10
1 open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
American University of Beirut Medical Center

Among the 10 studies testing inositol in Infertility, this one is the 6th largest by planned enrollment, is the only one that started in 2017, is one of 2 in phase 4, and was the 5th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 10 studies testing inositol in Infertility is open now, in 1 country.

By country, each count listing its studies:

Where they have run

About inositol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 18 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing inositol in Infertility, or all of them as a file.
02

Study summary

This is a prospective comparative randomized controlled study investigating the effect of Myo-Inositol-based co-treatment on oocyte quality measures in women with PCOS.

Read the detailed description

Polycystic Ovary Syndrome is the most common cause of chronic anovulation in women. Women with PCOS undergoing IVF are at an increased risk for developing both multiple gestation and ovarian hyperstimulation syndrome (OHSS). Since insulin resistance and hyperinsulinemia have been implicated in the pathophysiology of the disorder, the administration of metformin before or during an IVF cycle has been practiced for years in an attempt to improve follicular parameters necessary for reproductive success. Recently, a growing body of evidence has implicated alternative insulin sensitizing drugs, namely Myo-Inositol, in improving various manifestations of the disorder in this women population. Little has been done to evaluate the effect of Myo-Inositol co-treatment on the reproductive performance of PCOS women undergoing Assisted Reproductive Technologies (ART). In this prospective comparative randomized controlled study, women will be randomized into two groups: Women in the control group will receive folic acid daily. Women in the study group will receive Myo-Inositol, in combination with alpha- lipoic acid and cysteine, per day plus folic acid supplemented daily along with ovarian stimulation.

03

Conditions studied

  • Sterility
  • Infertility

Keywords

  • Polycystic Ovary Syndrome
  • Myo-Inositol
  • Assisted Reproductive Technology
  • oocyte performance
  • pregnancy
04

Who can participate

Ages eligible
18 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-40 years at the time of enrollment.
  • Women diagnosed with PCOS according to the Rotterdam criteria indicated by oligoamenorrhea (six or fewer menstrual cycles during a period of 1 year), hyperandrogenism (hirsutism, acne, or alopecia) or hyperandrogenemia (elevated levels of total or free T) and typical features of ovaries on ultrasound scan.
  • Planned IVF/ICSI treatment.
  • Normal uterine cavity (as assessed by hysteroscopy or HSG).
  • Normal hormonal investigation: TSH and PRL.

Exclusion criteria

Exclusion Criteria:

  • Azoospermia.
  • Other medical conditions causing ovulatory disorders, such as hyperprolactinemia, hypothyroidism, or adrenal hyperplasia.
  • to Myo-Inositol or its derivatives.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Myo-Inositol

    1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid

    Drug: Myo-inositol

  • No intervention
    No intervention

    Standard care: 400 ug of Folic acid

Interventions

  • DrugInositolStudies of InositolInositol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.

    Also known as: Celine

06

What researchers measure

Primary outcomes

  1. Oocyte yield

    Time frame: 1 day from ovum pick up

  2. Maturation rate

    Time frame: 1 day from ovum pick up

  3. Fertilization rate

    Time frame: 16-18 hours post insemination

Secondary outcomes

  1. Blood profile (fasting sugar and insulin levels, Testosterone, Sex Hormone-Binding protein, DHEAs, and Androstenedione)

    Time frame: Prior to and 6 weeks post enrollment

  2. Number of gonadotropin ampules

    Time frame: 1 day from oocyte maturation trigger

  3. Obstetrical outcome (preterm birth)

    Time frame: From 24 to 36 weeks gestation

  4. Obstetrical outcome (low birth weight)

    Time frame: From 24 to 36 weeks gestation

  5. Obstetrical outcome (gestational diabetes)

    Time frame: From 24 to 36 weeks gestation

  6. Obstetrical outcome (preeclampsia)

    Time frame: From 24 to 36 weeks gestation

  7. Obstetrical outcome (admission to neonatal intensive care)

    Time frame: From 24 to 36 weeks gestation

  8. Number of stimulation days

    Time frame: 1 day from oocyte maturation trigger

  9. Embryo quality

    Time frame: 3 to 5 days from ovum pick up

  10. Miscarriage rate

    Time frame: 7 weeks post LMP

  11. Ongoing pregnancy

    Time frame: 20 weeks post LMP

  12. Live birth rate

    Time frame: 24 to 42 weeks gestation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2017 (actual). Primary completion is estimated for Dec 2023, 81 months after the start.

Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 81 months is above that.

Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2017
First posted
Jun 6, 2017
StartActual
Mar 1, 2017
Primary completionEst.
Dec 1, 2023
CompletionEst.
Dec 31, 2023
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03177122
Responsible party
Johnny Awwad (Professor of Obstetrics and Gynecology, American University of Beirut Medical Center) — Principal investigator
First posted
Jun 6, 2017
Start date
Mar 1, 2017
Primary completion
Dec 1, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Jul 20, 2023

Study contacts

Johnny Awwad, MD
Contact
jawwad@aub.edu.lb
009611350000 ext. 5606
Layal Hamdar, MS
Contact
lh72@aub.edu.lb
009611350000 ext. 5606
Johnny Awwad, MD
principal investigator · American University of Beirut Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inositol

Start the discussion